Fig. 5: The differential expression of proteins and signaling pathways in HSG/HNSG. | Nature Communications

Fig. 5: The differential expression of proteins and signaling pathways in HSG/HNSG.

From: Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals potential therapeutic strategies

Fig. 5

a Kaplan–Meier plots show significant differences between the sensitive group (S) and non-sensitive group (NS) in overall survival (OS) (upper) and progression-free survival (PFS) (bottom) in the HER2 subcohort (two-sided log rank test). b Boxplot showing the ERBB2 expression in HSG (n = 32) and HNSG (n = 37) (two-sided Wilcoxon rank-sum test) (upper). Boxplots show median (central line), upper and lower quartiles (box limits), 1.5× interquartile range (whiskers). Cox analysis (two-sided Cox test) of ERBB2 with OS (bottom). c Heatmap showing the abundance of differentially expressed proteins in HSG and HNSG. d Pathway alterations in HSG and HNSG (two-sided Fisher’s exact test). e The GSEA enrichment analysis of ECM in HER2 subcohort (Nominal P value, calculated as Phenotype-based permutation test). The survival analysis of ssGSEA ECM pathway score with OS in HER2 subcohort (two-sided log rank test). f Heatmap illustrating the abundance of ECM proteins in HER2 subcohort and five gastric cancer cells (two-sided Wilcoxon rank-sum test). g, h Left panel: Correlation of ECM pathway score (g) and PI3K-AKT pathway score (h) with its downstream pathway assessed by ssGSEA (two-sided Pearson’s correlation test). Right panel: Heatmap illustrating the protein abundance of PI3K-AKT pathway (g) and apoptosis (h) related proteins (two-sided Wilcoxon rank-sum test). i Dose-response curves of NCI-N87 cells after 72-h treatments with buparlisib (BUP), trastuzumab (TRA), and combination of trastuzumab and buparlisib with a ratio of 1:1. IC50, half-maximal inhibitory concentration. The comparison of IC50 values of different therapies (two-sided Student’s t test). Bars represent the mean of n = 3 independent experiments with error bars indicating SD. j Diagram showing the potential mechanism of resistance to anti-HER2 targeted therapy. k The decision-making strategy for the GC therapy. *P < 0.05 is considered statistically significant. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Source data are provided as a Source Data file.

Back to article page